Nerviano Medical Sciences S.r.l. Announces Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) will be reported in an oral presentation by Dr. Maria Reig at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2022) which will be held October 26-28, 2022 at the CCIB in Barcelona.
Details of the upcoming oral presentation are as follows:
Title: NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma
Presenter: Dr. Maria Reig, Head of Liver Oncology Unit, Hospital Clinic Barcelona, Barcelona, Spain
Session: Plenary Session 7
Session Date/Time: Friday, October 28, 2022, 3:00 – 4:30 p.m. CET
Location: Room 111 + 112
The data are embargoed until the day of the presentation. A copy of the oral presentation will be available at www.nervianoms.com following presentation at the meeting.
About NMS-01940153E (NMS-153)
Primary liver cancer is the sixth most common neoplasm and among the leading cause of cancer-related death worldwide. HCC constitutes 80-90% of all primary liver cancers. Its incidence is increasing and will soon surpass one million annual cases worldwide. Most HCC cases are diagnosed at advanced stages and despite the recent approval of new therapeutic agents such as checkpoint inhibitors, there is a high unmet medical need.
NMS-153 is a highly potent and selective inhibitor of the MPS1 kinase, which is a mitotic regulator frequently overexpressed and activated in cancer. NMS-153 showed a broad preclinical activity in different tumor types, including HCC.
MPSA-153-001 is a Phase I/II study of NMS-153 administered as single agent in treatment experienced, unresectable HCC patients. The trial is currently open for enrollment